Pyxis Oncology's Cancer Drug Platform Shows Potential, Analyst Sees Over 190% Upside
Stephens has started coverage on Pyxis Oncology Inc (NASDAQ:PYXS), praising its innovative ADC technology targeting cancer treatment. The lead drug, PYX-201, shows promise in tumor treatment. With a positive outlook and upcoming trial results, Pyxis is poised for growth.